[1]杨柏帅,施裕新,袁 敏,等.TACE治疗既往有肝功能衰竭史肝癌患者七例[J].介入放射学杂志,2014,(09):805-808.
　YANG Bo shuai,SHI Yu xin,YUAN Min,et al.TACE treatment for patients with inoperable hepatocellular carcinoma and hepatic failure history： initial experience in seven cases[J].journal interventional radiology,2014,(09):805-808.
点击复制

TACE治疗既往有肝功能衰竭史肝癌患者七例 ()

PDF下载中关闭

分享到：

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
期数:
2014年09期
页码:
805-808
栏目:
临床研究
出版日期:
2014-09-25

文章信息/Info

Title:
TACE treatment for patients with inoperable hepatocellular carcinoma and hepatic failure history： initial experience in seven cases
作者:
杨柏帅;  施裕新;  袁 敏;  王介非;  周 粟;  王峻峰
Author(s):
YANG Bo shuai;  SHI Yu xin;  YUAN Min;  WANG Jie fei;  ZHOU Su;  WANG Jun feng.
Department of Radiology， Shanghai Public Health Center Affiliated to Fudan University， Shanghai 201508， China
关键词:
【关键词】 肝细胞肝癌;  肝衰竭;  经导管内动脉化疗栓塞术
文献标志码:
A
摘要:
【摘要】 目的 探讨TACE术在既往曾有肝功能衰竭的肝癌患者中应用的安全性和有效性。方法 既往有肝功能衰竭病史，接受TACE术的患者7例，既往肝功能衰竭痊愈距行TACE治疗时间平均3.5年。监测其术后不良反应，生化指标变化程度，至少随访6个月，与同期接受TACE术，且无肝功能衰竭病史的51例进行对比。结果 有肝功能衰竭史的患者，TACE术后随访期内无相关性死亡，未发生严重不良反应，轻度不良反应发生率与对照组无显著差异，术后短期内，与对照组相比，丙氨酸转氨酶、总胆红素、凝血酶原时间、白蛋白均有明显异常，但术后1个月，上述指标均能恢复，且术后6个月随访，两组肿瘤控制率无明显差异。结论 对于既往有肝功能衰竭病史，且有无法手术切除的肝癌患者，仍可行TACE术，且是一项安全的治疗手段。

参考文献/References:

［1］ Maluccio MA， Covey AM， Porat LB， et al. Transcatheter arterial embolization with only particles for the treatment of unresectable hepatocellular carcinoma［J］. J Vasc Interv Radiol， 2008， 19： 862 869.
［2］ Poon RT， Tso WK， Pang RW， et al. A phase Ⅰ/Ⅱ trial of chemoembolization for hepatocellular carcinoma using a novel intra arterial drug eluting bead［J］. Clin Gastroenterol Hepatol， 2007， 5： 1100 1108.
［3］ Poon RT， Ngan H， Lo CM， et al. Transarterial chemoembolization for inoperable hepatocellular carcinoma and postresection intrahepatic recurrence［J］. J Surg Oncol， 2000， 73： 109 114.
［4］ Dhanasekaran R， Kooby DA， Staley CA， et al. Comparison of conventional transarterial chemoembolization （TACE） and chemoembolization with doxorubicin drug eluting beads （DEB） for unresectable hepatocelluar carcinoma （HCC）［J］. J Surg Oncol， 2010， 101： 476 480.
［5］ El Serag Hb MJ， treatment of hepatocellular carcinoma. Gastroenterology［J］. 期刊名称缺失， 2008， 134： 1752 1763.
［6］ 季玉峰， 程永德． 肝动脉化疗栓塞治疗难治性肝癌的若干问题［J］． 介入放射学杂志， 2006， 15： 705 706．
［7］ Morse MA， Hanks BA， Suhocki P， et al. Improved time to progression for transarterial chemoembolization compared with transarterial embolization for patients with unresectable hepatocellular carcinoma［J］. Clin Colorectal Cancer， 2012， 11： 185 190. 

相似文献/References:

[1]邢桃红,牛焕章,周媛媛,等. TACE联合索拉非尼治疗23例中晚期肝细胞肝癌的护理[J].介入放射学杂志,2014,(05):449.
　XING Tao- hong,NIU Huan- zhang,ZHOU Yuan- yuan,et al. Nursing for patients with advanced hepatocellular carcinoma receiving transcatheter arterial chemoembolization combined with sorafenib： initial experience in 23 cases[J].journal interventional radiology,2014,(09):449.
[2]阿布都外力·吾布力卡斯穆,迪里木拉提·巴吾冬,任伟新. 巴塞罗那肝癌B期患者TACE治疗的预后及生存分析[J].介入放射学杂志,2014,(05):435.
　ABUDUWAILI Obulikasimu,DILMURAT Bawudun,REN Wei- xin.. Transcatheter arterial chemoembolization for the treatment of Barcelona stage B hepatocellular carcinoma： analysis of the prognosis and survival[J].journal interventional radiology,2014,(09):435.
[3]王 龙,张 勇,王亚运,等.125I粒子联合经导管动脉化疗栓塞治疗肝细胞肝癌伴门静脉癌栓临床有效性与安全性meta 分析[J].介入放射学杂志,2018,27(05):419.
　WANG Long,ZHANG Yong,WANG Yayun,et al.125I seed implantation combined with TACE for the treatment of HCC complicated by portal vein tumor thrombus： a meta- analysis of its clinical effectiveness and safety[J].journal interventional radiology,2018,27(09):419.
[4]杨柏帅,施裕新,袁 敏,等.终末期肾衰竭肝癌患者TACE术中应用洛铂治疗3例[J].介入放射学杂志,2016,(05):381.
　YANG Bo- shuai,SHI Yu- xin,YUAN Min,et al.Transcatheter arterial chemoembolization using lobaplatin and lipiodol for the treatment of hepatocellular carcinoma associated with end- stage renal failure： report of three cases[J].journal interventional radiology,2016,(09):381.
[5]许 贇,沈 强,王 能,等.微波消融治疗＞70岁早期肝细胞肝癌患者效果分析[J].介入放射学杂志,2016,(04):332.
　XU Yun,SHEN Qiang,WANG Neng,et al.Effect analysis of microwave ablation therapy for early hepatocellular carcinoma in patients over 70 years old[J].journal interventional radiology,2016,(09):332.
[6]吴志远,丁晓毅,黄 蔚,等.门脉粒子支架联合载药微球栓塞治疗肝癌7例[J].介入放射学杂志,2017,(02):161.
　WU Zhiyuan,DING Xiaoyi,HUANG Wei,et al.Portal 125I seed stent implantation combined with drug-loaded microsphere embolization for the treatment of HCC： initial results in 7 patients[J].journal interventional radiology,2017,(09):161.
[7]王 燕,王茂强,段 峰.索拉非尼治疗中晚期肝癌预后因素分析[J].介入放射学杂志,2017,(03):258.
　WANG Yan,WANG Maoqiang,DUAN Feng.Prognostic factor analysis of moderate- advanced hepatocellular carcinoma treated with sorafenib [J].journal interventional radiology,2017,(09):258.
[8]余天柱,罗剑钧,颜志平.血管内近程放疗与序贯三维适形放疗治疗门静脉主干癌栓的疗效对比 [J].介入放射学杂志,2017,(09):787.
　YU Tianzhu,LUO Jianjun,YAN Zhiping.Endovascular brachytherapy vs. sequential three- dimensional conformal radiotherapy for the treatment of main portal vein tumor thrombus： a comparative study[J].journal interventional radiology,2017,(09):787.
[9]贾中芝,顾晓诚,蒋国民.门静脉癌栓分型对肝细胞性肝癌治疗方法的选择及患者预后的影响 [J].介入放射学杂志,2017,(10):944.
　JIA Zhongzhi,GU Xiaocheng,JIANG Guomin.The application of portal vein tumor thrombus classification in selecting therapeutic method for HCC patients and in estimating the prognosis[J].journal interventional radiology,2017,(09):944.
[10]刘璐璐,章浙伟,杨永波,等.CT灌注参数动脉增强分数值在评估肝癌TACE术后疗效中的初步研究 [J].介入放射学杂志,2017,(11):988.
　LIU Lulu,ZHANG Zhewei,YANG Yongbo,et al.Application of quantitative arterial enhancement fraction of multiphase perfusion CT imaging in evaluating the curative effect of transcatheter arterial chemoembolization for hepatocellular carcinoma[J].journal interventional radiology,2017,(09):988.

备注/Memo

备注/Memo:
（收稿日期：２０１3-12-23）
（本文编辑：俞瑞纲）
更新日期/Last Update: 2014-09-18